Details of the Drug Excipient

General Information of Drug Inactive Ingredient (DIG) (ID: E00102)

DIG Name	Sodium citrate anhydrous
Synonyms	Sodium citrate; TRISODIUM CITRATE; 68-04-2; Natrocitral; Sodium citrate anhydrous; sodium citrate, anhydrous; Citric acid, trisodium salt; Trisodium citrate, anhydrous; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, trisodium salt; Sodium 2-hydroxypropane-1,2,3-tricarboxylate; Trisodium citrate anhydrous; FEMA No. 3026; Citric acid trisodium salt; UNII-RS7A450LGA; Sodium citrate,anhydrous; MFCD00012462; RS7A450LGA; Citrosodine; CHEBI:53258; Citric acid trisodium salt, anhydrous; CITRIC ACID, SODIUM SALT; Citrosodina; Citnatin; Citreme; Citrosodna; Sodium citrate hydrate; trisodium;2-hydroxypropane-1,2,3-tricarboxylate; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, sodium salt (1:3); CCRIS 3293; Sodium citrate (Na3C6H5O7); HSDB 5201; anhydrous sodium citrate; 994-36-5; Citric acid, trisodium salt, 98%, pure, anhydrous; EINECS 200-675-3; trisodium-citrate; tri-sodium citrate; Trisodium 2-hydroxy-1,2,3-propanetricarboxylate; sodium citrate salt; sodium (iii) citrate; Sodium citrate (USP); Anhydrous trisodium citrate; EC 200-675-3; C6H5Na3O7; Anticoagulant Sodium Citrate; trisodium 2-hydroxypropane-1,2,3-tricarboxylate; CHEMBL1355; INS NO.331(III); INS-331(III); DTXSID2026363; 2-Hydroxy-1,2,3-propanetricarboxylic acid, trisodium salt; Citric acid sodium salt anhydrous; Citric acid trisodium salt, 99%; E-331(III); CS-B1704; AKOS015915009; FEMA NO. 3026, ANHYDROUS-; Citrate Solution, pH ~3.0, 30 mM; DB09154; AC-15008; E331; K121; Sodium citrate dihydrate USP Fine Granular; B7298; FT-0623960; 1835-EP2269978A2; 1835-EP2269985A2; 1835-EP2269991A2; 1835-EP2270017A1; 1835-EP2270505A1; 1835-EP2272817A1; 1835-EP2272822A1; 1835-EP2272843A1; 1835-EP2275413A1; 1835-EP2277565A2; 1835-EP2277566A2; 1835-EP2277567A1; 1835-EP2277568A2; 1835-EP2277569A2; 1835-EP2277570A2; 1835-EP2277867A2; 1835-EP2280003A2; 1835-EP2280010A2; 1835-EP2281559A1; 1835-EP2281817A1; 1835-EP2281818A1; 1835-EP2281823A2; 1835-EP2284150A2; 1835-EP2284151A2; 1835-EP2284152A2; 1835-EP2284153A2; 1835-EP2284155A2; 1835-EP2284156A2; 1835-EP2284160A1; 1835-EP2284164A2; 1835-EP2287140A2; 1835-EP2287148A2; 1835-EP2287150A2; 1835-EP2287155A1; 1835-EP2287156A1; 1835-EP2287160A1; 1835-EP2287163A1; 1835-EP2289871A1; 1835-EP2289893A1; 1835-EP2292227A2; 1835-EP2292280A1; 1835-EP2292590A2; 1835-EP2292611A1; 1835-EP2292612A2; 1835-EP2295402A2; 1835-EP2295406A1; 1835-EP2295414A1; 1835-EP2295416A2; 1835-EP2295419A2; 1835-EP2295426A1; 1835-EP2295427A1; 1835-EP2295437A1; 1835-EP2298731A1; 1835-EP2298732A1; 1835-EP2298734A2; 1835-EP2298735A1; 1835-EP2298748A2; 1835-EP2298772A1; 1835-EP2298775A1; 1835-EP2301534A1; 1835-EP2301912A2; 1835-EP2301913A1; 1835-EP2301914A1; 1835-EP2301916A2; 1835-EP2301941A1; 1835-EP2305243A1; 1835-EP2305637A2; 1835-EP2305657A2; 1835-EP2305678A1; 1835-EP2308510A1; 1835-EP2308562A2; 1835-EP2308832A1; 1835-EP2308839A1; 1835-EP2308861A1; 1835-EP2308863A1; 1835-EP2308872A1; 1835-EP2308873A1; 1835-EP2308875A1; 1835-EP2311451A1; 1835-EP2311796A1; 1835-EP2311797A1; 1835-EP2311798A1; 1835-EP2311799A1; 1835-EP2311807A1; 1835-EP2311821A1; 1835-EP2311823A1; 1835-EP2311831A1; 1835-EP2311837A1; 1835-EP2311842A2; 1835-EP2314575A1; 1835-EP2314584A1; 1835-EP2314586A1; 1835-EP2314593A1; 1835-EP2316450A1; 1835-EP2316459A1; 1835-EP2316470A2; 1835-EP2316829A1; 1835-EP2316831A1; 1835-EP2316834A1; 1835-EP2316836A1; 1835-EP2316937A1; 1835-EP2371811A2; 1835-EP2374454A1; 1835-EP2380568A1; D05855; N-1560; 88676-EP2272841A1; 88676-EP2280001A1; 88676-EP2301936A1; 88676-EP2305825A1; Sodium citrate, 0.5M buffer solution, pH 5.0; Sodium citrate, 0.5M buffer solution, pH 5.5; Sodium citrate, 0.5M buffer solution, pH 6.0; Sodium citrate, 0.5M buffer solution, pH 6.5; Q409728; J-520101; Citric acid trisodium salt, anhydrous, >=98% (GC); Citrate Solution, pH 3.6+/-0.1 (25 C), 27 mM; Citric acid trisodium salt, Vetec(TM) reagent grade, 98%; UNII-1Q73Q2JULR component HRXKRNGNAMMEHJ-UHFFFAOYSA-K; 2-Hydroxy-1,2,3-propanenetricarboxylic acid trisodium salt dihydrate; Citrate Concentrated Solution, BioUltra, for molecular biology, 1 M in H2O; Buffer solution pH 5.0 (20 C), citric acid ~0.096 M, sodium hydroxide ~0.20 M; Citrate Concentrated Solution, BioReagent, suitable for coagulation assays, 4 % (w/v)
DIG Function	Alkalizing agent; Buffering agent; Complexing agent; Emulsifying agent
Formula	C6H5Na3O7
Canonical SMILES	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Na+].[Na+].[Na+]
InChI	1S/C6H8O7.3Na/c7-3(8)1-6(13,5(11)12)2-4(9)10;;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;;/q;3*+1/p-3
InChIKey	HRXKRNGNAMMEHJ-UHFFFAOYSA-K
Physicochemical Properties	Molecular Weight	258.07	Topological Polar Surface Area	141
	XlogP	N.A.	Complexity	211
	Heavy Atom Count	16	Rotatable Bond Count	2
	Hydrogen Bond Donor Count	1	Hydrogen Bond Acceptor Count	7

Full List of Drug(s) Co-administrated with This DIG

26 Approved Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
Acetaminophen	DMUIE76	Pain [MG30-MG3Z]	Acetaminophen 500 mg tablet	F00459
Alprostadil	DMWH7NQ	Diabetic foot ulcer [BD54]	Alprostadil 0.01mg/vial injectable	F23614
Amikacin	DM5PDRB	Bacterial infection [1A00-1C4Z]	Amikacin eq 250mg injectable	F23622
Amoxicillin	DMUYNEI	Bacterial infection [1A00-1C4Z]	Amoxicillin 125 mg tablet	F01238
Atropine	DMEN6X7	Organophosphate poisoning [NE6Z]	Atropine 0.25mg/0.3ml solution	F24299
Buprenorphine	DMPRI8G	Pain [MG30-MG3Z]	Buprenorphine 2 mg tablet	F02774
Calcipotriol	DM03CP7	Psoriasis vulgaris [EA90]	Calcipotriene 0.005% solution	F23661
Carvedilol	DMHTEAO	Congestive heart failure [BD10]	Carvedilol 12.5 mg tablet	F03422
Dextromethorphan	DMUDJZM	Cough [MD12]	Dextromethorphan 15mg/5ml Syrup	F23419
Erythromycin	DM4K7GQ	Bacterial infection [1A00-1C4Z]	Erythromycin 250 mg tablet	F07360
Etoposide	DMNH3PG	Solid tumour/cancer [2A00-2F9Z]	Etoposide Phosphate eq 100mg base/vial injectable	F24243
Flurandrenolide	DMHCI9S	Inflammation [1A00-CA43.1]	Flurandrenolide 0.05% cream	F23172
Flurbiprofen	DMGN4BY	Rheumatoid arthritis [FA20]	Flurbiprofen Sodium 0.03% solution	F23344
Ibuprofen	DM8VCBE	Pain [MG30-MG3Z]	Ibuprofen 400 mg tablet	F10375
Ingenol mebutate	DMK1CZJ	Actinic keratosis [EK90.0]	Ingenol Mebutate 0.015% gel	F24066
Isoproterenol	DMK7MEY	Heart block [BC63]	Isoproterenol 1mg/5ml solution	F23796
Meloxicam	DM2AR7L	Arthritis [FA20]	Meloxicam 15 mg tablet	F12877
Nafcillin	DMN9RPO	Arthritis [FA20]	Nafcillin 1g powder	F23832
Naphazoline	DMJFZDL	Hyperaemia [9A61-9B7Y]	Naphazoline 0.05% solution	F23837
Oxymetazoline	DM8ZXT6	Eye inflammation [9A02]	Oxymetazoline 0.1% solution	F23855
Penicillin V	DMKVOYF	Bacterial infection [1A00-1C4Z]	Penicillin V 250 mg tablet	F16753
Pramipexole	DMNMW9R	Parkinson disease [8A00.0]	Pramipexole 0.5 mg tablet	F17524
Procaine	DM4LSNE	Anaesthesia [9A78.6]	Procaine 300000 units/ml injectable	F24383
Quetiapine	DM1N62C	Schizophrenia [6A20]	Quetiapine 50 mg tablet	F18545
Revefenacin	DMMP5SI	Chronic obstructive pulmonary disease [CA22]	Revefenacin 175 mcg/3 ml solution	F23271
Rosuvastatin	DMMIQ7G	Hypercholesterolaemia [5C80.0]	Rosuvastatin 20 mg tablet	F19633
------------------


⏷ Show the Full List of 26 Approved Drug(s)

2 Investigative Drug(s) Co-administrated with This DIG

Drug Name	Drug ID	Indication	Formulation Name	Formulation ID
Brominide tartrate	DMMC4BY	Discovery agent [N.A.]	Brimonidine Tartrate 0.2% solution	F23653
Oxybutynine	DMJPBAX	Discovery agent [N.A.]	Oxybutynin 5mg/5ml Syrup	F23501
------------------